Can the halp score, a new prognostic tool, predict the progression of pseudoexfoliation patients to pseudoexfoliation glaucoma?
dc.contributor.author | Akbulut Yağcı, Betül | |
dc.contributor.author | Erdal, Hüseyin | |
dc.date.accessioned | 2025-07-24T11:15:12Z | |
dc.date.available | 2025-07-24T11:15:12Z | |
dc.date.issued | 2025 | |
dc.department | Tıp Fakültesi | |
dc.description.abstract | The present study aims to investigate the prognostic role of hemoglobin, albumin, lymphocyte, and platelet (HALP) score in pseudoexfoliation syndrome (PEXS) patients and its relationship with pseudoexfoliation glaucoma (PEXG) progression. Material and Methods: This retrospective study included 58 PEXS and 61 PEXG patients. All groups ' demographic information and hemograms, s were collected from the hospital automation system. The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), systemic immuno-inflammatory index (SII), systemic inflammatory response index (SIRI), pan-immune inflammation value (PIV), and HALP were calculated to both groups. The results were compared among the groups. Results: In this study, there were 119 participants in total: 58 patients with PEXS with an average age of 71.3 +/- 8.9 years and 61 patients with PEXG with an average age of 71.3 +/- 8.9 years (p=0.15). In paired comparisons, it was observed that the NLR, PLR, SII, SIRI, and PIV indices of the groups were not found to be statistically significant (p>0.001). The HALP score value was lower in the PEXG group than the PEXS (4.73 +/- 1.99 and 6.3 +/- 2.63, respectively) (p<0.001). The AUC of the HALP score for PEXS and PEXG was 0.696. The optimal cut-off value of HALP to predict PEXG was <= 4.23, with 85% sensitivity and 51.7% specificity (95% confidence interval 0,605-0,777, p<0.01). Discussion: It was found that a lower HALP score was significantly associated with PEXG patients and could be an independent prognostic factor. Although this score alone is not sufficient, this study is important in that it may predict the possibility of developing PEXG. | |
dc.identifier.doi | 10.4328/ACAM.22378 | |
dc.identifier.endpage | 275 | |
dc.identifier.issn | 2667-663X | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 272 | |
dc.identifier.uri | https://dx.doi.org/10.4328/ACAM.22378 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12451/13567 | |
dc.identifier.volume | 16 | |
dc.identifier.wos | WOS:001462328500008 | |
dc.identifier.wosquality | Q4 | |
dc.indekslendigikaynak | Web of Science | |
dc.institutionauthor | Akbulut Yağcı, Betül | |
dc.institutionauthor | Erdal, Hüseyin | |
dc.publisher | Bayrakol MP | |
dc.relation.ispartof | Annals of Clinical and Analytical Medicine | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Halp Score | |
dc.subject | Pseudoexfoliation Glaucoma | |
dc.subject | Pseudoexfoliation Syndrome | |
dc.title | Can the halp score, a new prognostic tool, predict the progression of pseudoexfoliation patients to pseudoexfoliation glaucoma? | |
dc.type | Article |